LEF1 and endometrial carcinoma: Given the high degree (>95%) of identity between mouse and human Lef1 protein orthologs, we are confident that the mouse system represents a reliable in vivo model in which to test potential therapies that are based on regulation of the Wnt/β-catenin/Lef1 pathway for their effectiveness in slowing the growth of endometrial carcinomas.